Novartis Current Share Price | Novartis Stock Screener
NOVARTIND
Pharmaceuticals
Novartis Current Stock Price Today
Live Share Price NSE
₹2046.80
▼
-35.40 (-1.70%)
Live Share Price BSE
₹2057.50
▼
-23.35 (-1.12%)
As of September 18, 2026, the live Novartis share price (NSE: NOVARTIND) is ₹2,046.80 on NSE and ₹2,057.50 on BSE, down 1.70% from the previous close, with shares trading between ₹2,006.00 and ₹2,154.90 in today's trading session, and a 52-week range of ₹962.00–₹2,428.20.
Browse Novartis annual reports to support your investment research.
Use the Novartis stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Novartis Market Cap
₹4,927.05 Cr.
NOVARTIND P/E Ratio (TTM)
55.29
Novartis P/B Ratio
6.61
EPS (TTM)
₹37.74
Dividend Yield
1.14%
Debt to Equity
0.01
NOVARTIND 52 Week High
₹2428.20
Novartis 52 Week Low
₹962.00
Operating Margin
27.00%
Profit Margin
24.02%
NOVARTIND Revenue (TTM)
₹408.00
EBITDA
₹139.00
Net Income
₹98.00
Total Assets
₹978.00
Total Equity
₹818.00
Novartis Current Share Price Chart
Track the current Novartis share price and stock price with an interactive chart. Analyse NOVARTIND price trends, trading volume, historical performance, and volatility across different timeframes — the complete Novartis stock quote in one place.
Novartis Company Profile - Fundamental Screener
Screen Novartis company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for NOVARTIND shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE234A01025
Novartis Balance Sheet Screener
Screen NOVARTIND balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 978 | 948 | 925 | 983 | 958 | 1,002 | 1,078 | 982 | 1,111 | 1,150 |
| Current Assets | 768 | 746 | 699 | 677 | 709 | 723 | 813 | 807 | 952 | 973 |
| Fixed Assets | 3 | 5 | 7 | 19 | 24 | 64 | 76 | 15 | 5 | 6 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 16 | 21 | 23 | 48 | 50 | 132 | 124 | 38 | 47 | 47 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 818 | 785 | 745 | 776 | 692 | 711 | 721 | 759 | 734 | 920 |
| Share Capital | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 14 |
| Reserves & Surplus | 806 | 773 | 733 | 763 | 679 | 699 | 708 | 747 | 721 | 906 |
Novartis Income Statement Screener - Profit & Revenue Analysis
Screen Novartis income statement and profit fundamentals.
Analyze NOVARTIND quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Novartis share price evaluation.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 408 | 393 | 398 | 397 | 437 | 433 | 414 | 474 | 569 | 736 | 727 | 771 | 981 |
| Expenses | 269 | 260 | 265 | 270 | 314 | 373 | 355 | 426 | 478 | 570 | 631 | 656 | 877 |
| EBITDA | 139 | 133 | 133 | 127 | 123 | 60 | 60 | 48 | 91 | 166 | 96 | 115 | 104 |
| Operating Profit % | 27.00% | 27.00% | 26.00% | 19.00% | 17.00% | 7.00% | 7.00% | 3.00% | 3.00% | -1.00% | 4.00% | 5.00% | 0.00% |
| Depreciation | 2 | 2 | 2 | 3 | 6 | 10 | 12 | 13 | 3 | 3 | 4 | 4 | 4 |
| Interest | 1 | 1 | 1 | 2 | 2 | 5 | 8 | 6 | 2 | 6 | 1 | 0 | 0 |
| Profit Before Tax | 136 | 130 | 130 | 123 | 115 | -4 | 40 | 29 | 86 | 158 | 92 | 111 | 93 |
| Tax | 37 | 37 | 30 | 38 | 12 | 0 | 19 | 19 | 34 | 79 | 35 | 39 | 14 |
| Net Profit | 98 | 93 | 101 | 85 | 103 | -4 | 21 | 10 | 52 | 78 | 57 | 73 | 79 |
| EPS | 39.60 | 37.74 | 40.87 | 34.50 | 41.86 | -1.51 | 8.46 | 4.08 | 20.97 | 28.43 | 19.10 | 62.04 | 24.75 |
Novartis Cash Flow Screener - Liquidity Fundamentals
Screen NOVARTIND cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 47 | 75 | 113 | 45 | 39 | -69 | -23 | -194 | 161 | -41 |
| Investing Activities | 18 | -3 | 33 | -153 | 87 | 95 | 56 | 274 | 69 | 424 |
| Financing Activities | -64 | -64 | -121 | -31 | -36 | -37 | -41 | -30 | -268 | -332 |
| Net Cash Flow | 0 | 7 | 26 | -139 | 90 | -11 | -9 | 50 | -38 | 51 |
Novartis Shareholding Pattern Screener
See Novartis shareholding pattern with promoter, FII, and DII holdings.
Check Novartis promoter holding and ownership changes for NOVARTIND on TickJournal.
| Item | 2026-Mar | 2026-Jun | 2026-Jul | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% |
| FII Holding | 0.17% | 0.16% | 0.15% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% |
| DII Holding | 0.53% | 1.36% | 1.39% | 0.53% | 0.53% | 0.53% | 0.64% | 0.53% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 23.25% | 22.50% | 22.43% | 23.11% | 22.95% | 22.92% | 22.67% | 22.95% |
| Other Holding | 5.36% | 5.31% | 5.35% | 5.49% | 5.66% | 5.68% | 5.83% | 5.65% |
| Shareholder Count | 38,116 | 36,502 | 36,706 | 39,133 | 39,040 | 39,353 | 39,468 | 41,239 |
Novartis Share Dividend Screener - Share Yield Analysis
Check Novartis dividend history with payout and yield data.
View Novartis dividend details including ex-dates and amounts for NOVARTIND stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹25.00 | 1.14% |
| 2025-March | ₹25.00 | 2.58% |
| 2024-March | ₹25.00 | 3.18% |
| 2023-March | ₹47.50 | 7.07% |
| 2022-March | ₹10.00 | 1.77% |
| 2021-March | ₹10.00 | 1.70% |
| 2020-March | ₹10.00 | 1.81% |
| 2019-March | ₹10.00 | 1.99% |
| 2018-March | ₹10.00 | 1.46% |
| 2017-March | ₹10.00 | 1.63% |
Novartis Stock Index Membership
See which indices include Novartis stock.
Check NOVARTIND index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
Novartis Market Events Screener - Corporate Actions
Get Novartis corporate actions including splits, bonuses, and buybacks.
Check Novartis stock events that may affect NOVARTIND share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-24 | 2026-09-24 | Annual General Meeting | NA | 36.62% |
| 2026-07-23 | 2026-07-23 | Quarterly Result Announcement | NA | 16.63% |
| 2026-05-12 | 2026-05-12 | Quarterly Result Announcement | NA | 21.81% |
| 2026-01-28 | 2026-01-28 | Quarterly Result Announcement | NA | 3.23% |
| 2025-10-28 | 2025-10-28 | Quarterly Result Announcement | NA | -3.77% |
| 2025-07-31 | 2025-07-31 | Annual General Meeting | NA | 24.87% |
| 2025-07-29 | 2025-07-29 | Quarterly Result Announcement | NA | -0.92% |
| 2025-07-23 | 2025-07-23 | Dividend | ₹ 25.00 /share | 33.11% |
| 2025-05-09 | 2025-05-09 | Quarterly Result Announcement | NA | -3.94% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | -4.09% |
| 2024-10-25 | 2024-10-25 | Quarterly Result Announcement | NA | -9.21% |
| 2024-07-31 | 2024-07-31 | Annual General Meeting | NA | 11.66% |
| 2024-07-23 | 2024-07-24 | Dividend | ₹ 25.00 /share | 5.99% |
| 2023-07-20 | 2023-07-21 | Dividend | ₹ 10.00 /share | 32.63% |
| 2023-07-20 | 2023-07-21 | Dividend | ₹ 37.50 /share | 32.63% |
Novartis Competitors Screener - Peer Comparison
Screen NOVARTIND competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 444,717 | 36.34 | 61,674 | 12.69% | 11,565 | 38.94 |
| Divis Laboratories | 243,116 | 83.41 | 11,067 | 13.95% | 2,568 | 57.81 |
| Torrent Pharmaceuticals | 183,052 | 85.57 | 13,886 | 20.34% | 2,138 | 42.03 |
| Zydus Life Science | 111,440 | 23.87 | 27,658 | 17.64% | 5,026 | 43.86 |
| Cipla | 109,705 | 32.76 | 29,045 | 2.24% | 3,870 | 35.04 |
| Laurus Labs | 102,870 | 95.29 | 6,868 | 22.01% | 890 | 56.63 |
| Dr Reddys Laboratories | 95,152 | 30.15 | 35,059 | 3.90% | 4,158 | 39.81 |
| Aurobindo Pharma | 94,535 | 25.82 | 34,145 | 5.56% | 3,503 | 49.75 |
| Lupin | 93,504 | 16.93 | 29,039 | 26.75% | 5,356 | 22.87 |
| Mankind Pharma | 92,759 | 45.72 | 14,636 | 14.85% | 1,938 | 34.16 |
Novartis Company Announcements - News Screener
Screen NOVARTIND latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-09-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-09-14 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-09-13 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-09-11 | Intimation Pursuant To Regulation 36(1)(B) Of SEBI LODR Regulations | - |
| 2026-09-10 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-09-10 | Intimation Under Reg 30 Of SEBI LODR Regarding Entering Into Exclusive Promotion And Distribution Agreement With Novartis Healthcare Private Limited | - |
| 2026-09-09 | Intimation Regarding The Acquisition Of Trademarks "Minipress" And "Minipres" From Pfizer Inc. USA And Pfizer Products Inc. USA The Same Is Approved By The Board Of Directors Of The Company At Their Board Meeting Held Today I.E. September 07 2026 | - |
| 2026-09-03 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-02 | Reg. 34 (1) Annual Report. | - |
| 2026-09-02 | Notice Of The 78Th Annual General Meeting Of Novartis India Limited To Be Held On Thursday September 24 2026 Through Video Conferencing (VC) / Other Audio Visual Means (OAVM) | - |
| 2026-09-02 | Business Responsibility and Sustainability Reporting (BRSR) | - |
| 2026-08-28 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-17 | Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of The Company Held On August 17 2026 | - |
| 2026-08-07 | Board Meeting Outcome for Outcome Of The Board Meeting Held On August 07 2026 | - |
| 2026-07-29 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-07-29 | Outcome Of The 247Th Meeting Of The Board Of Directors Held Today I.E Wednesday July 29 2026. | - |
| 2026-07-29 | Outcome Of The 246Th Meeting Of The Board Of Directors Held On Today I.E Wednesday July 29 2026. | - |
| 2026-07-29 | Announcement under Regulation 30 (LODR)-Resignation of Chairman | - |
| 2026-07-29 | Announcement under Regulation 30 (LODR)-Resignation of Director | - |
| 2026-07-29 | Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) | - |